Jason Theola, Muhammad Ikrar Hermanadi, Kahlil Gibran, Syarifaha Ihsan
{"title":"伊维菌素治疗COVID-19的临床结果:来自系统评价和荟萃分析的循证病例报告","authors":"Jason Theola, Muhammad Ikrar Hermanadi, Kahlil Gibran, Syarifaha Ihsan","doi":"10.53366/jimki.v9i2.411","DOIUrl":null,"url":null,"abstract":"Background: Ivermectin has demonstrated beneficial results on clinical outcomes in COVID-19 patients. Several countries have included ivermectin in their guidelines, though WHO recommended against its usage. Therefore, this study was aimed to establish the clinical outcomes of ivermectin in COVID-19 patients by an evidence-based method. \nMethod: Article searching was completed in PubMed, Cochrane, and Scopus from July 9 - 10 2021. The results were limited to only systematic reviews and meta-analyses. Hand searching was conducted to obtain relevant studies from external resources. The results were evaluated using inclusion and exclusion criteria. The full texts were obtained and critically reviewed using Oxford Centre for Evidence-Based Medicine critical appraisal tools. \nResult: Three systematic reviews and meta-analyses were selected and critically reviewed. All three studies were considered valid, important, and applicable. However, the quality of these studies varied from low to high. \nConclusion: Overall studies showed that ivermectin has the potential to improve clinical outcomes in COVID-19 patients.","PeriodicalId":14697,"journal":{"name":"JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CLINICAL OUTCOMES OF IVERMECTIN IN COVID-19 TREATMENT: AN EVIDENCE-BASED CASE REPORT FROM SYSTEMATIC REVIEWS AND META-ANALYSES\",\"authors\":\"Jason Theola, Muhammad Ikrar Hermanadi, Kahlil Gibran, Syarifaha Ihsan\",\"doi\":\"10.53366/jimki.v9i2.411\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Ivermectin has demonstrated beneficial results on clinical outcomes in COVID-19 patients. Several countries have included ivermectin in their guidelines, though WHO recommended against its usage. Therefore, this study was aimed to establish the clinical outcomes of ivermectin in COVID-19 patients by an evidence-based method. \\nMethod: Article searching was completed in PubMed, Cochrane, and Scopus from July 9 - 10 2021. The results were limited to only systematic reviews and meta-analyses. Hand searching was conducted to obtain relevant studies from external resources. The results were evaluated using inclusion and exclusion criteria. The full texts were obtained and critically reviewed using Oxford Centre for Evidence-Based Medicine critical appraisal tools. \\nResult: Three systematic reviews and meta-analyses were selected and critically reviewed. All three studies were considered valid, important, and applicable. However, the quality of these studies varied from low to high. \\nConclusion: Overall studies showed that ivermectin has the potential to improve clinical outcomes in COVID-19 patients.\",\"PeriodicalId\":14697,\"journal\":{\"name\":\"JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-11-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.53366/jimki.v9i2.411\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53366/jimki.v9i2.411","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
CLINICAL OUTCOMES OF IVERMECTIN IN COVID-19 TREATMENT: AN EVIDENCE-BASED CASE REPORT FROM SYSTEMATIC REVIEWS AND META-ANALYSES
Background: Ivermectin has demonstrated beneficial results on clinical outcomes in COVID-19 patients. Several countries have included ivermectin in their guidelines, though WHO recommended against its usage. Therefore, this study was aimed to establish the clinical outcomes of ivermectin in COVID-19 patients by an evidence-based method.
Method: Article searching was completed in PubMed, Cochrane, and Scopus from July 9 - 10 2021. The results were limited to only systematic reviews and meta-analyses. Hand searching was conducted to obtain relevant studies from external resources. The results were evaluated using inclusion and exclusion criteria. The full texts were obtained and critically reviewed using Oxford Centre for Evidence-Based Medicine critical appraisal tools.
Result: Three systematic reviews and meta-analyses were selected and critically reviewed. All three studies were considered valid, important, and applicable. However, the quality of these studies varied from low to high.
Conclusion: Overall studies showed that ivermectin has the potential to improve clinical outcomes in COVID-19 patients.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
